Table 4

Autoantibodies in different disease subsets in 863 individual systemic sclerosis patients

Limited (N = 513)

Diffuse (N = 173)

Overlap (N = 108)

Undifferentiated (N = 64)


Antibodies

n (%)

ORa (P-value)

n (%)

OR (P-value)

n (%)

OR (P-value)

n (%)


ACA

253 (49.3)

5.00 (P < 0.0001)

12 (6.9)

16 (14.8)

28 (43.8)

ATA

141 (27.5)

98 (56.6)

4.26 (P < 0.0001)

11 (10.2)

9 (14.1)

Anti-RNAP

14 (2.7)

14 (8.1)

3.11 (P = 0.0029)

2 (1.9)

2 (3.1)

Anti-U1-RNP

7 (1.4)

0 (0.0)

31 (28.7)

30.00 (P < 0.0001)

2 (3.1)

Anti-PM-Scl

16 (3.1)

2 (1.2)

22 (20.4)

9.40 (P < 0.0001)

2 (3.1)

Anti-fibrillarin

3 (0.6)

8 (4.6)

8.32 (P = 0.0005)

1 (0.9)

0 (0.0)

Anti-To

1 (0.2)

0 (0)

1 (0.9)

0 (0.0)

Anti-Jo-1/Pl-7/OJ

0 (0.0)

0 (0)

4 (3.7)

65.07 (P = 0.0002)

0 (0.0)

Anti-U11-RNP

0 (0.0)

1 (0.6)

0 (0.0)

0 (0.0)

Anti-Ku

5 (1.0)

1 (0.6)

3 (2.8)

1 (1.6)

Anti-SL

5 (1.0)

3 (1.7)

1 (0.9)

0 (0.0)

Anti-Sm

0 (0.0)

0 (0.0)

3 (2.8)

21.54 (P = 0.0069)

0 (0.0)

Anti-NOR-90

5 (1.0)

0 (0.0)

1 (0.9)

0 (0.0)

AMA

28 (5.5)

4 (2.3)

4 (3.7)

5 (7.8)

Anti-Sp100

3 (0.6)

0 (0.0)

0 (0.0)

1 (1.6)

Anti-Ro52

125 (24.4)

1.50 (P = 0.023)

20 (11.6)

27 (25.0)

15 (23.4)

Anti-Ro60

28 (5.4)

14 (8.1)

13 (12.0)

2.11 (P = 0.0382)

4 (6.3)

Anti-La

9 (1.8)

3 (1.7)

1 (0.9)

3 (4.7)

Anti-p25/p23

24 (4.5)

4.25 (P = 0.0031)

0 (0.0)

2 (1.9)

2 (3.1)

Other

209 (40.7)

74 (42.8)

44 (40.7)

34 (53.1)

ANA-negative

32 (6.2)

6 (3.5)

5 (4.6)

7 (10.9)


ACA, anti-centromere antibodies; AMA, antimitochondrial antibodies; ANA, antinuclear antibodies; ATA, anti-topoisomerase I antibodies; RNAP, RNA polymerase;. aOR for antibody in that subset compared with all other subsets. Only significant positive associations are documented by OR, and those with P-values < 0.005 are printed in bold.

Mierau et al. Arthritis Research & Therapy 2011 13:R172   doi:10.1186/ar3495

Open Data